What are the characteristics and recommended treatment options for signet‑ring cell carcinoma?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 15, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Signet Ring Cell Carcinoma: Characteristics and Treatment

For gastric signet ring cell carcinoma (SRCC), patients with multiple lesions or hereditary diffuse gastric cancer (HDGC) features should undergo CDH1 genetic testing, and treatment should prioritize curative surgical resection with standardized lymphadenectomy over perioperative chemotherapy in early-stage disease, as neoadjuvant chemotherapy is an independent poor prognostic factor in advanced SRCC 1, 2.

Key Characteristics

Histopathology and Classification

  • Defining feature: ≥50% of tumor cells contain abundant intracytoplasmic mucin with peripherally displaced nucleus creating the characteristic "signet ring" appearance 3
  • Classification systems: In Japan and South Korea, use the Japanese Gastric Cancer Association classification rather than the Laurén classification for gastric SRCC 1
  • Gastric SRCC: Represents the diffuse type, characterized by poorly differentiated, discohesive tumor cells diffusely infiltrating the gastric wall in a desmoplastic stroma 4

Clinical Presentation Patterns

  • Age: Disproportionately affects younger adults compared to conventional adenocarcinomas 5, 3
  • Location:
    • Gastric SRCC: More prevalent in low-risk geographic areas, associated with heritable genetic abnormalities 4
    • Colorectal SRCC: More common in right colon (56.89% vs. 32.12% for conventional adenocarcinoma) 5
  • Stage at diagnosis: Presents at more advanced stages—37.88% stage III and 45.25% stage IV for colorectal SRCC 5
  • Tumor grade: 62.71% poorly differentiated in colorectal SRCC vs. 14.12% in conventional adenocarcinoma 5

Aggressive Biological Behavior

  • Growth pattern: Diffuse infiltrative growth with peritoneal dissemination 3
  • Metastatic pattern: Higher rates of bone and distant lymph node metastasis (3.3% and 63.7% respectively in colorectal SRCC) 5
  • Chemoresistance: Less chemosensitive than other subtypes; increasing percentage of signet ring cells correlates with resistance to chemotherapy 2

Survival Outcomes

Colorectal SRCC 5:

  • Median survival: 17 months vs. 59 months for conventional adenocarcinoma
  • 5-year survival: 5.9% vs. 46.9%

Gastric SRCC 6:

  • 5-year OS/CSS: 6.3%/7.7% vs. 18.2%/23.0% for colorectal SRCC
  • Critical finding: Colorectal SRCC demonstrates significantly superior survival compared to gastric SRCC (HR: 0.62, P < 0.001) 6

Genetic Testing Indications

CDH1/CTNNA1 Testing Criteria (2020 Guidelines)

Offer genetic testing for 1:

  • Isolated diffuse gastric cancer diagnosed <50 years (expanded from <40 years)
  • Patients with multiple signet ring cell carcinoma lesions identified endoscopically or in gastrectomy specimens
  • Women with bilateral lobular breast cancer <70 years
  • All New Zealand Māori with confirmed diffuse gastric cancer (13% carry pathogenic CDH1 variants)
  • Personal or family history of cleft lip/palate with diffuse gastric cancer
  • Testing sequence: Analyze CDH1 first; if negative, consider CTNNA1 analysis

Genetic Counseling Requirements

  • Evaluate three-generation family pedigree
  • Document any cleft lip/palate history
  • Obtain histopathological confirmation of cancer diagnoses
  • Discuss prophylactic total gastrectomy (PTG) benefits/risks and long-term sequelae
  • Offer reproductive genetic counseling to carriers of childbearing age 1

Stage-Stratified Treatment Approach

Early-Stage Disease (Stage I-II)

Primary strategy: Aggressive surgical resection 2, 7:

  • Endoscopic resection: Only for carefully selected early lesions with favorable characteristics
  • Radical surgery with standardized lymphadenectomy: Gold standard treatment
  • Avoid perioperative chemotherapy: Neoadjuvant treatment is an independent poor prognostic factor in advanced SRCC due to chemoresistance and toxicity 2

Advanced Disease (Stage III-IV)

Optimal approach: Surgery + chemotherapy 6:

  • Surgery + chemotherapy demonstrated improved OS and CSS in both gastric and colorectal SRCC cohorts regardless of stage III/IV status
  • This combination was superior to surgery alone, chemotherapy alone, or no therapy
  • Gastric SRCC: Chemotherapy alone was most frequent (39.3%), but surgery + chemotherapy showed better outcomes 6
  • Colorectal SRCC: Surgery + chemotherapy predominated (47.5%) and remained the most effective approach 6

Site-Specific Considerations

Gastric SRCC 2, 7:

  • Curative surgical resection with standardized lymphadenectomy remains the recommended gold standard
  • Perioperative chemotherapy should be avoided in advanced SRCC due to poor chemosensitivity
  • Early detection and aggressive surgical treatment is the most reasonable approach

Colorectal SRCC 5, 6:

  • Comprehensive treatment including surgery, chemotherapy, and radiotherapy remains optimal
  • Incorporate lymph node positive rate (LNR) grouping for prognostic stratification
  • Surgery + chemotherapy improves survival even in stage IV disease

Molecular Mechanisms and Future Directions

Key Molecular Pathways 8, 7:

  • ErbB2/ErbB3-MUC4 axis: Abnormal activation
  • PI3K and MAPK pathways: Activated
  • KRAS mutations: Frequent in pancreatic SRCC
  • Microsatellite instability: May be present in some cases 9

Emerging Therapies 8, 7:

  • Targeted therapy: KRAS mutation-targeted agents under investigation
  • Immunotherapy: PD-L1 targeting may provide benefit, particularly in microsatellite-unstable tumors
  • Personalized multimodal treatment: Based on molecular profiling and tumor characteristics

Critical Pitfalls to Avoid

  1. Diagnostic challenges 3:

    • SRCC can masquerade as inflammatory disease
    • Superficial biopsies may be non-diagnostic
    • Carcinoembryonic antigen (CEA) may be within normal range despite advanced disease
    • Maintain high clinical suspicion in younger patients with obstructive symptoms

  2. Treatment errors 2:

    • Do not routinely use perioperative chemotherapy in advanced gastric SRCC—it worsens prognosis
    • Recognize that standard chemotherapy regimens (5-FU, epirubicin, cisplatin, capecitabine, docetaxel) have poor efficacy in SRCC
    • Avoid delaying surgery for neoadjuvant therapy in resectable disease

  3. Prognostic stratification 5, 6:

    • Independent prognostic factors: Age, primary site, stage, treatment modality, marital status
    • Primary site matters: Colorectal SRCC has significantly better prognosis than gastric SRCC
    • Higher signet ring cell percentage correlates with worse chemotherapy response

  4. Genetic testing oversights 1:

    • Test patients with multiple SRCC lesions, not just solitary tumors
    • Expanded age criteria now include isolated cases up to age 50 (not just <40)
    • Multigene panel testing may identify unexpected CDH1 variants requiring specialized counseling

References

4
Guideline

gastric cancer, version 2.2022, nccn clinical practice guidelines in oncology.

Journal of the National Comprehensive Cancer Network : JNCCN, 2022

Related Questions

In the adjuvant setting for a stage IIA (pT3 pN0) signet‑ring cell adenocarcinoma of the ascending colon that is poorly differentiated (grade 3) with small‑vessel invasion, what is the benefit of a three‑month CAPOX (capecitabine plus oxaliplatin) regimen?
What are the treatment guidelines for a patient diagnosed with signet ring cell gastric carcinoma?
Does applying a 10% benzyl benzoate preparation to a healthy 4‑year‑old girl carry a risk of adverse effects?
Are dysgeusia, anorexia, respiratory infection, and diarrhea related to venetoclax or epcoritamab?
How should the bronze-colored hyperpigmentation of skin in iron overload be described?
What are the causes of tubulointerstitial kidney disease?
What is the recommended management and treatment for a patient with primary antiphospholipid syndrome (APS) presenting with severe thrombocytopenia?
What is the recommended steroid dosing regimen for Wegener's granulomatosis (granulomatosis with polyangiitis)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.